Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Directorate Change

EKF Diagnostics Holdings plc (AIM: EKF), which has recently refocused on the in-vitro diagnostic devices market, announces that David Evans (formerly Non-Executive Chairman) has today been appointed Executive Chairman of the Company.

Mr. Evans was appointed to the Board on 26th November 2009 when the Company announced a change in strategy to focus on building a business within the diagnostics market place through acquisition and organic growth. Since his appointment the Company has successfully acquired EKF-diagnostic GmbH, through a reverse takeover and has continued to divest itself from the sports apparel industry. With David's wealth of experience and success within the diagnostic and healthcare industry and in particular at this stage of the Company's development the Board of directors decided that it would be in shareholders best interests to appoint David to the position of Executive Chairman. 

In addition the Board announces that David's remuneration will be at the same level as previously agreed for his non-executive role at £40,000 per annum and he would like to receive this in new equity to be issued every six months, based upon the average share price during this period.

Julian Baines, EKF's CEO, commented: "I am delighted David has accepted this role as I have worked with him for a number years and hugely value his support and wealth of knowledge within the industry. David's contribution working alongside me as an executive will be invaluable at this stage of the Company's pro-active buy and build strategy."

Enquiries: